Bacterial News and Research

RSS

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Latest LLMDA technology available to detect viruses, bacteria

Law enforcement authorities seeking to detect bioterrorism attacks, doctors diagnosing diseases and regulatory agencies checking product safety may find a new ally in a Lawrence Livermore National Laboratory detection technology.

6 May 2010

New combination eye drops effective in treating bacterial keratitis

Scientists are reporting development of a potential new way of enabling patients with bacterial keratitis to stick with the extraordinarily intensive treatment needed for this potentially blinding eye infection.

6 May 2010

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.

5 May 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Natural S-equol, a novel soy germ-based compound, is very likely the primary ingredient for reducing hot flushes in the dietary supplement SE5-OH, which is under development for reduction of menopause symptoms, according to pre-clinical efficacy data from studies using an animal model presented at the Experimental Biology 2010 annual meeting.

3 May 2010

Study could provide new strategies to prevent hospital-acquired infections

A bacterial pathogen can communicate with yeast to block the development of drug-resistant yeast infections, say Irish scientists writing in the May issue of Microbiology. The research could be a step towards new strategies to prevent hospital-acquired infections associated with medical implants.

3 May 2010

Opinions: Sanitation and women, child health; GM in Global Food Security bill; U.S. malaria strategy; GHI on NTDs; Haiti recovery

"If Stephen Harper is serious about maternal health and child health [as suggested by his plans for the upcoming G8 and G20 summits], he needs to recognize that healthy mothers come from healthy communities," Maude Barlow and Meera Karunananthan of the Council of Canadians write in a Chronicle Herald opinion piece that examines the connections between the health of women and children and access to drinking water and sanitation.

30 Apr 2010

Gonorrhea may soon become untreatable according to WHO

According to the World Health organization (WHO), gonorrhea may soon become untreatable and urgent measures need to be taken to prevent and treat the sexually transmitted infection. This is the result of improper use of first line antibiotics which has led to widespread anti microbial resistance to drugs. The cheaper antibiotics no longer have as much effect as they should and the higher antibiotics will soon lose efficacy as well.

30 Apr 2010

Air pollution can damage heart and lead to increased risk of heart disease: Study

A post-mortem study of the hearts of 21 young people in Mexico City has found that the heart begins to show the adverse effects of air pollution at a young age and that tiny bits of inactivated bacteria that hitch a ride on pollutants may make the problem worse.

29 Apr 2010

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination antibiotics effectively treat Chlamydia-induced reactive arthritis - a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

29 Apr 2010

New study reinforces urgent need for life-saving vaccines in Africa

A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus - a bacterial infection that causes pneumonia, meningitis and sepsis - are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death.

29 Apr 2010

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that it will be presenting three separate presentations at the Cambridge Healthtech Institute's 4th Annual Antibacterial Drug Development Conference, Resistance is Futile: The Challenge of Antibacterial Drug Development, April 27 - 28, in San Diego, CA.

27 Apr 2010

CocE exhibits potential for clinical treatment of cocaine toxicity

Cocaine toxicity due to drug overdose results in more than half a million emergency room visits annually. Despite these alarming statistics, there is no Food and Drug Administration-approved pharmacotherapy specifically designed to treat cocaine toxicity. Emergency medical personnel are limited to treating only the immediate life-threatening symptoms of patients, while toxic levels of cocaine and its metabolic break-down products persist and continue to damage the cardiovascular system, liver and brain.

27 Apr 2010

MorphoSys AG reports Q1 results for 2010

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the three months ending March 31, 2010 according to International Financial Reporting Standards (IFRS).

27 Apr 2010

Fever in kids underestimated by Doctors: new study

In a new study researchers have found that some physicians may be missing the seriousness of an infection in a child presenting with fever. The study published in the British Medical Journal involved 16,000 children from 2004 to 2006 with fever and found that doctors could not diagnose up to one third of the potentially life-threatening illnesses in these children.

27 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

Enhancing residence time improves drug effectivity: Study

Studies led by Stony Brook University professor of chemistry Peter J. Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.

26 Apr 2010

Bacterial News and Research

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

Latest LLMDA technology available to detect viruses, bacteria

New combination eye drops effective in treating bacterial keratitis

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Study could provide new strategies to prevent hospital-acquired infections

Opinions: Sanitation and women, child health; GM in Global Food Security bill; U.S. malaria strategy; GHI on NTDs; Haiti recovery

Gonorrhea may soon become untreatable according to WHO

Air pollution can damage heart and lead to increased risk of heart disease: Study

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

New study reinforces urgent need for life-saving vaccines in Africa

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

CocE exhibits potential for clinical treatment of cocaine toxicity

MorphoSys AG reports Q1 results for 2010

Fever in kids underestimated by Doctors: new study

Caltech biologists offer new insight into causes of IBD and colon cancer

Enhancing residence time improves drug effectivity: Study

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News